
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is well-positioned for success with a promising pipeline of potential treatments for a variety of classical complement-mediated diseases, including autoimmune and neurodegenerative disorders, as well as ocular diseases. Their lead program for GBS has already shown positive results and their drug vonaprument has a high potential for success in Phase 3 trials. Investors can also be reassured by the company's strong leadership, including the Executive Vice President who is leading innovation and scientific strategy, and the potential for significant peak sales of $500 million.
Bears say
Annexon is currently in the clinical stage and has no approved products on the market, leaving the potential for future revenue uncertain. Additionally, the company's financials show a decrease in total assets and an increase in liabilities, indicating potential financial struggles. With competition in the C1q inhibition market and the uncertainty of future success, Annexon's stock may see a decline in the coming years.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares